The Metabolic Fingerprint of Doxorubicin-Induced Cardiotoxicity in Male CD-1 Mice Fades Away with Time While Autophagy Increases
The cardiotoxicity of doxorubicin (DOX) may manifest at the beginning/during treatment or years after, compromising patients’ quality of life. We intended to study the cardiac pathways one week (short-term, control 1 [CTRL1] and DOX1 groups) or five months (long-term, CTRL2 and DOX2 groups) after DO...
Main Authors: | Sofia Reis Brandão, Ana Reis-Mendes, Maria João Neuparth, Félix Carvalho, Rita Ferreira, Vera Marisa Costa |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-11-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/16/11/1613 |
Similar Items
-
Demystifying the Relationship Between Metformin, AMPK, and Doxorubicin Cardiotoxicity
by: Manrose Singh, et al.
Published: (2022-01-01) -
Molecular alterations underlying Doxorubicin’s Chronic Cardiotoxicity in a mouse model
by: Sofia Reis Brandão, et al.
Published: (2022-04-01) -
In the Heart of Cardio-Oncology: The Targets and Biomarkers of Cardiotoxicity in Anticancer Drugs
by: Vera Marisa Costa
Published: (2022-11-01) -
Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase
by: Anchit Bhagat, et al.
Published: (2022-08-01) -
Influence of trimetazidine on myocardium energy balance during chemotherapy with doxorubicin and cyclophosphamide
by: A. A. Avagimyan
Published: (2022-06-01)